Skip to Main Content
U.S. Department of Health & Human Services » National Institutes of Health
National Heart, Lung, and Blood Institute
Login | Register

Biologic Specimen and Data Repository Information Coordinating Center

  • Home (current)
  • About BioLINCC
    • About Us
    • FAQ
    • Contact Us
    • Glossary
  • Biospecimen and Data Resources
    • Overview
    • Studies
    • Teaching Datasets - Public Use Datasets
    • Renew Existing Data Use Agreement
    • Publications
    • Funding Opportunities
    • Non-BioLINCC Resources
    • Covid-19 Resources
  • Procedures and Forms
    • BioLINCC Handbook
    • Form Templates
    • Agreement Templates
  • Build/Submit New Collection
    • Informed Consent Considerations
    • NHLBI Biorepository Guide
    • Submit Datasets
    • Submit Biospecimens and Datasets
Home > Studies > REDS II-MS > Catalog

Retrovirus Epidemiology Donor Study-II (REDS II) Molecular Surveillance (MS) - Catalog

Basic Study Information

Name

Retrovirus Epidemiology Donor Study-II (REDS II) Molecular Surveillance (MS)

Accession Number

HLB00961212a

Acronym

REDS II-MS

Related studies

BSI Study IDs
Is public use dataset

False

Keywords

Has Study Datasets

True

Has Specimens

False

Specimen ID Type

Not Applicable (Data Only)

Study Website

The Framingham Heart Study Group requires that the requestor must obtain full or expedited IRB/Ethics Committee review and approval to obtain these data. Waivers or a determination that the research is exempt from ethical regulations do not suffice.

False

Clinical Trial URLs
https://clinicaltrials.gov/ct2/show/NCT00097006
Study type

Epidemiology Study

Collection Type

Open BioLINCC Study

Cohort type

Adult

Interventions

Study Open Date (Data)

2012-11-19

Study Open Date (Specimens)

2012-11-19

Date materials available

2012-11-16

Last updated

2019-05-10

Study period

2006 - 2009

Study Contacts
NHLBI Division

DBDR

Classification

Transfusion Medicine

HIV study classification

HIV

COVID study classification

non-COVID

Pre-Website # of Specimens Shipped

0

# of Returned Specimens

0

Primary Publication URLs
https://www.ncbi.nlm.nih.gov/pubmed/22293432

Study Consent

Commercial use data restrictions

No

Data restrictions based on area of research

No

Commercial use specimen restrictions

Not Applicable (Data Only)

Non-genetic use specimen restrictions based on area of use

Not Applicable (Data Only)

Genetic use of specimens allowed?

Not Applicable (Data Only)

Genetic use area of research restrictions

Not Applicable (No Genetic Use Specimens)

Specific Consent Restrictions

Additional Study Information

Conditions

Acquired Immunodeficiency Syndrome
Blood Donors
Blood Transfusion
HIV Infections
HIV-1
HIV-2
HTLV-I
HTLV-II
Hepacivirus
Hepatitis B
Hepatitis, Viral, Human
Retroviridae Infections
West Nile Virus

Objectives

The objective of the study was to conduct a genetic analysis of incident and prevalent strains of HIV, HCV and HBV by testing blood specimens from HIV, HCV or HBV positive blood donors who gave blood at REDS-II centers, as well as at UBS, NYBC and ARC blood centers between 2006 and 2009.

Background

Genetic variations of human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV) can affect diagnostic assays and therapeutic interventions. Recent changes in prevalence of subtypes/genotypes and drug/immune-escape variants were characterized by comparing recently infected vs. more remotely infected blood donors.

Subjects

This study included qualifying donations from 1 January 2006 through 31 December 31 2009 from 3 Retrovirus Epidemiology Donor Study-II (REDS-II) blood centers (Blood Centers of the Pacific, Blood Center of Wisconsin, and Hoxworth Blood Center/University of Cincinnati), all American Red Cross Blood Services regions, United Blood Services regions and the New York Blood Center. Together, these centers account for approximately 70% of the US blood supply.

Design

Infected donors were identified among approximately 34 million US blood donations, 2006–2009 based on screening and confirmatory tests for HIV and HCV nucleic acid testing, HIV and HCV antibody, HBsAg, and anti-HBV core antibody; incident infections were defined as having no or low antiviral antibody titers. Viral genomes were partially sequenced.

Conclusions

Viral genetic variant distribution in blood donors was similar to that seen in high-risk US populations. Blood-borne viruses detected through large-scale routine screening of blood donors can complement molecular surveillance studies of highly exposed populations. (Delwart et. al. 2012)

Disease classification

Publications

Mat types

Study Population

The study population available in BioLINCC study data may be lower than total study enrollment due to Informed Consent restrictions and other factors.

  • Subjects

    12118


    Last Modified: July 28, 2014, 2:40 p.m.
  • Age

     

    Frequency

    Percent

    16-20

    1442

    11.90

    21-25

    897

    7.40

    26-30

    877

    7.24

    31-35

    815

    6.73

    36-40

    1038

    8.57

    41-45

    1429

    11.79

    46-50

    2002

    16.52

    51-55

    1856

    15.32

    56-60

    1035

    8.54

    61-65

    379

    3.13

    66-70

    179

    1.48

    71-75

    93

    0.77

    76-80

    49

    0.40

    81-85

    16

    0.13

    >=86

    11

    0.09

     

    Last Modified: Aug. 25, 2015, 4:04 p.m.
  • Sex

     

    Frequency

    Percent

    NOT AVAILABLE

    3

    0.02

    FEMALE

    4366

    36.03

    MALE

    7749

    63.95

     

    Last Modified: Aug. 25, 2015, 4:04 p.m.
  • Race

     

    Frequency

    Percent

    REFUSED

    4

    0.03

    NOT AVAILABLE

    2621

    21.63

    ASIAN

    966

    7.97

    BLACK

    1823

    15.04

    HISPANIC

    918

    7.58

    NATIVE AMERICAN

    91

    0.75

    WHITE

    5352

    44.17

    MORE THAN ONE RACE

    57

    0.47

    OTHER

    286

    2.36

     

    Last Modified: March 11, 2016, 2:48 p.m.
  • About Us
  • FAQ
  • Glossary
  • Contact
  • Privacy Policy
  • Accessibility
  • FOIA
  • HHS Vulnerability Disclosure

  • U.S. Department of Health & Human Services
  • National Institutes of Health
  • National Heart, Lung, and Blood Institute
  • USA.gov
NIH… Turning Discovery Into Health®